|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | |||
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. | SEC 1474 (9-02) |
1. Title of Derivative Security (Instr. 3) |
2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) |
5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) |
6. Date Exercisable and Expiration Date (Month/Day/Year) |
7. Title and Amount of Underlying Securities (Instr. 3 and 4) |
8. Price of Derivative Security (Instr. 5) |
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) |
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) |
11. Nature of Indirect Beneficial Ownership (Instr. 4) |
||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Reporting Owner Name / Address | Relationships | |||
Director | 10% Owner | Officer | Other | |
Musket David B 125 CAMBRIDGEPARK DR. CAMBRIDGE, MA 02140 |
X | |||
KUROKAWA BARRY 125 CAMBRIDGEPARK DR. CAMBRIDGE, MA 02140 |
Joint filer | |||
PROMED ASSET MANAGEMENT, LLC 125 CAMBRIDGEPARK DRIVE CAMBRIDGE, MA 02140 |
Joint Filer | |||
PROMED MANAGEMENT INC 125 CAMBRIDGEPARK DR. CAMBRIDGE, MA 02140 |
Joint Filer |
/s/ David B. Musket | 02/06/2007 | |
**Signature of Reporting Person | Date | |
/s/ Barry Kurokawa | 02/06/2007 | |
**Signature of Reporting Person | Date | |
/s/ Promed Asset Management LLC | 02/06/2007 | |
**Signature of Reporting Person | Date | |
/s/ Promed Management Inc. | 02/06/2007 | |
**Signature of Reporting Person | Date |
* | If the form is filed by more than one reporting person, see Instruction 4(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
(1) | The reported sale was made on behalf of the account of ProMed Offshore Fund, Ltd., a private investment fund ("ProMed Offshore"), whose investment manager is ProMed Management Inc. ("Promed Inc."). The remainder of the reported amount of securities beneficially owned following the reported transaction may be deemed to be owned by (i) David B. Musket, (ii) Barry Kurokawa, (iii) (ProMed Partners, L.P., a private investment fund ("ProMed I"), whose general partner and investment manager are ProMed Asset Management, L.L.C. ("PAM") and ProMed Inc., respectively and (iv) ProMed Partners II, L.P., a private investment fund ("ProMed II"), whose general partner and investment manager are PAM and ProMed Inc., respectively. Both PAM and ProMed Inc. are controlled by David B. Musket and Barry Kurokawa. |
(2) | Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
(3) | The reported sale was made on behalf of ProMed I. The remainder of the reported amount of securities beneficially owned following the reported transaction may be deemed to be owned by (i) David B. Musket, (ii) Barry KuroKawa, (iii) ProMed II and (iv) ProMed Offshore. |